Galam
1
11M
1
0.01
1
- Areas of investment
Summary
Galam is the famous Corporate Investor, which was founded in 1940.
The standard case for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Ofer Hi-Tech, Millennium II Materials Technology Fund, Arancia International. In the next rounds fund is usually obtained by TPY Capital, Frutarom.
Among the most popular portfolio startups of the fund, we may highlight Enzymotec. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular fund investment industries, there are Manufacturing, Biotechnology.
The fund is generally included in less than 2 deals every year. The increased amount of exits for fund were in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2009.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.01
- Investments by industry
- Biotechnology (1)
- Manufacturing (1)
- Health Care (1)
- Investments by region
-
- Israel (1)
- Peak activity year
- 2009
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
- Avg. valuation at time of investment
- 290M
- Group Appearance index
- 1.00
- Avg. company exit year
- 19
- Avg. multiplicator
- 8.55
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Enzymotec | 02 Feb 2009 | Biotechnology, Health Care, Manufacturing | Early Stage Venture | 11M | Israel, North District, Migdal HaEmek |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.